Main Answer:
Tadalafil (Cialis) has been approved as a phosphodiesterase (PDE) inhibitor for treating benign prostatic hyperplasia (BPH). a. tadalafil (Cialis).
Therefore, the correct answer is a. tadalafil (Cialis).
Explanation:
While Andy may be surprised, this medication is not only prescribed for erectile dysfunction but has also demonstrated efficacy in alleviating symptoms associated with BPH.
Tadalafil belongs to the class of PDE inhibitors, specifically PDE-5 inhibitors, which work by relaxing the smooth muscles in the prostate and bladder. This mechanism of action helps improve urine flow and reduce symptoms like frequent urination, urgency, and difficulty initiating urination. Although widely known for its use in erectile dysfunction, the approval of tadalafil for BPH emphasizes its versatility in addressing different medical conditions.
It's important to note that not all PDE inhibitors are approved for treating BPH. Viagra (sildenafil), for instance, primarily focuses on erectile dysfunction and is not indicated for BPH. The distinction in approval highlights the specific pharmacological profile of tadalafil that makes it suitable for addressing both BPH and erectile dysfunction.
In summary, the surprising prescription of tadalafil for Andy's BPH is justified by its approval as a PDE inhibitor for this condition, showcasing the diverse therapeutic applications of this medication.
Therefore, the correct answer is a. tadalafil (Cialis).